Research
Hormonal
GLP-1RA medications are effective in achieving optimal glucose control and reducing all-cause death, cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, and end-stage kidney disease in individuals with type 1 and type 2 diabetes.
GLP-1RA medications can be considered for improving glucose control and reducing serious health risks in diabetic patients.
StrongSupportsmedium confidence
Glucagon-like peptide-1 receptor agonist (GLP-1RA) medications have been shown to be effective in achieving optimal glucose control and reducing all-cause death, cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, and end-stage kidney disease in individuals with type 1 (T1D) and type 2 diabetes (T2D).
Why this rating
The claim is based on established findings regarding GLP-1RA medications.
Source
Use of continuous glucose monitoring when initiating <scp>glucagon‐like peptide</scp> ‐ <scp>1 receptor agonist</scp> therapy in insulin‐treated diabetes
Irl B. Hirsch et al. · Diabetes Obesity and Metabolism · 2024
reviewCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →